Mana.bio
Omri Amirav-Drory is a board member at Mana.bio. Omri was previously the CEO of resistanceBio, a Talus Bio, La Jolla Labs, Mana.bio, PANGEA Therapeutics, Pepper Bio, Nanocarry Therapeutics, Gilboa Therapeutics, and NFX.
Omri Amirav-Drory has a postdoctoral in Biochemistry and Molecular Biology from Stanford University, a Doctor of Philosophy (Ph.D.) in Biochemistry from Tel Aviv University, and a Bachelor of Science - BS in Biochemistry and Molecular Biology from Tel Aviv University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mana.bio
Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.